"Use of Cyclin-dependent Kinase (CDK) 4/6 Inhibitors for Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative, Metastatic Breast Cancer: a Roundtable Discussion by The Breast Cancer Therapy Expert Group (BCTEG)" by Reshma Mahtani

Article

Use of Cyclin-dependent Kinase (CDK) 4/6 Inhibitors for Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative, Metastatic Breast Cancer: a Roundtable Discussion by The Breast Cancer Therapy Expert Group (BCTEG)

Breast Cancer Research and Treatment (2018)

Reshma Mahtani, Baptist Health South Florida
Jame Abraham
Robert Coleman
Anthony Elias
Frankie Ann Holmes
Kevin Kalinsky
Muaiad Kittaneh
Elyse Lower
E. Terry Mamounas
Mark Pegram
Charles L. Vogel, University of Miami
Breast Cancer Therapy Expert Group (BCTEG)

Link

Disciplines

Medicine and Health Sciences

Publication Date

May 4, 2018

Citation Information

Reshma Mahtani, Jame Abraham, Robert Coleman, Anthony Elias, et al.. "Use of Cyclin-dependent Kinase (CDK) 4/6 Inhibitors for Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative, Metastatic Breast Cancer: a Roundtable Discussion by The Breast Cancer Therapy Expert Group (BCTEG)" Breast Cancer Research and Treatment Vol. 171 (2018) p. 11 - 20
Available at: http://works.bepress.com/reshma-mahtani/85/